Extended-spectrum ␤-lactamases (ESBL) of the CTX-M, SHV, and TEM families were recognized in 76 (67%), 31 (27%), and 6 (5%) isolates, respectively, among 162 ESBL-producing Klebsiella pneumoniae (ESBLKp) strains obtained in a multicenter study in Spain. Predisposing factors for ESBL-Kp acquisition included invasive procedures, mechanical ventilation, and previous antimicrobial use.
different antibiogram type (Ͼ4-fold difference in the MICs of at least two agents of different biochemical groups) for patterns including 2 to 4 isolates, and (iii) two isolates of every different antibiogram type (as defined above) for patterns including Ն5 isolates. Selection was done on plates containing either cefotaxime (2 mg/liter) or ampicillin (100 mg/liter). ESBL production was confirmed in transconjugants by disk diffusion (disks from Oxoid, United Kingdom) according to CLSI guidelines (4) . ␤-Lactamase genes were detected by PCR and sequencing in the parental isolates selected for conjugation studies or in derived transconjugants, using previously described primers and conditions for TEM (19) , SHV (19) , and CTX-M (18) enzymes. CTX-M groups were determined according to the method of Woodford et al. (22) . CTX-M-15 was differentiated from CTX-M-28 by PCR as described previously (13a). Epidemiological and clinical data from patients in whom ESBL-producing Klebsiella pneumoniae (ESBL-Kp) was isolated were collected using a structured questionnaire. ESBL-Kp strains isolated after 48 h of hospital admission were considered nosocomially acquired (NA) (11) . Among the rest, ESBL-Kp strains were considered health care associated (HCA) if the patient was admitted to an acute-or long-termcare center or received hemodialysis, specialized home care, or care in a day hospital during the preceding 3 months. All other isolates were considered to be community acquired (CA). Qualitative variables were compared using the chi-square test or the Fisher exact test as appropriate. The project was approved by the Ethic Committee of the Hospital Universitario Virgen Macarena, which waived the need for informed consent due to the observational nature of the study.
ESBL-Kp strains were isolated in 32 out of the 44 (72.7%) participating centers. In all, 162 isolates (1 to 16 per center), corresponding to 80 clones (1 to 9 per center), were obtained. A predominant clone was present in a specific hospital in most cases, although in 12 and 8 centers, Ն3 and 2 clones were identified, respectively.
The results of susceptibility testing are presented in Table 1 . One (0.6%) isolate was susceptible to cefotaxime, 7 (4.3%) and 12 (7.4%) isolates were intermediate and susceptible to ceftazidime, respectively, 14 (8.6%) and 13 (8.0%) were intermediate and susceptible to cefepime, respectively, and 4 (2.5%) and 11 (6.8%) were intermediate and susceptible to aztreonam, respectively. However, whether the patients from whom ESBL-Kp strains susceptible to expanded-spectrum cephalosporins or aztreonam were isolated may respond satisfactorily when treated with these agents is not yet completely defined. Carbapenems were very active, and only 2 (1.2%) and 1 (0.6%) isolates were resistant and intermediate to ertapenem, respectively. Amikacin and tigecycline also presented good in vitro activity against the tested isolates. ESBL-Kp isolates in Spain in 2006 were more resistant than the isolates studied in 2000 to amoxicillin-clavulanate, piperacillin-tazobactam, ciprofloxacin, and co-trimoxazole (Table 1) . Increased resistance to amoxicillin-clavulanate might be related to the dissemination of plasmids coding for CXT-M-15 (see below) that usually also contain other determinants of resistance to this combination. The decreased activity of ciprofloxacin may be related in part to the presence of aac(6Ј)-Ib-cr, which was detected in 34.2% of 114 isolates studied (unpublished data).
In 2006, ESBL were identified in 105 out of the 114 (92.1%) isolates. The ESBL identified in 2006 clearly differ from those observed in 2000 (12, 13 ). An SHV amplicon was obtained in 107 (93.8%) of these 114 parental isolates, but an SHV-type ESBL was identified in only 31 isolates, of which 21 contained SHV-12, 6 contained SHV-2, 3 contained SHV-5, and 1 contained SHV-33. The remaining 76 SHV amplicons presumably correspond to the non-ESBL variants of the chromosomal SHV enzyme of K. pneumoniae. Sequencing in 37 randomly chosen isolates from which SHV-type enzymes were not identified in transconjugants confirmed in all cases the presence of either SHV-1 (21 isolates; 56.8%) or SHV-11 (16 isolates; 43.2%). A gene coding for a TEM enzyme was detected in 55 (48.2%) out of the 114 parental isolates, but a TEM-type ESBL was demonstrated in only 6 (5.3%) transconjugants Isolates with CTX-M-15 were present in 18 hospitals, and those with SHV-12 were present in 14 centers. CTX-M-14 and CTX-M-1 were also broadly distributed (each enzyme in strains from 8 centers). This distribution of ESBL among K. pneumoniae strains mirrors that obtained in the E. coli strains isolated during the same period (9) .
ESBL-Kp strains were obtained from 133 adults and 29 pediatric patients (of whom 26 were from neonates). Complete clinical data were available for 102 adults and 23 neonates ( Table 2) . Acquisition was considered nosocomial for 85 (64%) adult patients admitted to medical services (35 patients), surgical services (25 patients), or intensive care units (ICUs) (25 patients). Acquisition of the pathogen was health care associated for 28 (21%) adults (22 received specialized ambulatory care, 10 had previous hospital admission, 3 were nursing home residents, and 1 was on hemodialysis). For the remaining 17 (13%) adults, a strict community origin was considered. One hundred three out of the 133 (77%) adult patients were considered to have an infection. Clustered isolates were more frequently nosocomial than nonnosocomial (77% versus 59%; P ϭ 0.01), while sporadic isolates were more frequently strictly community acquired than health care related or nosocomial (17% versus 6%; P ϭ 0.01). The most frequent ESBL in adults were CTX-M-15 (47 isolates), SHV-12 (29 isolates), and CTX-M-14 (18 isolates). Empirical therapy was inappropriate in about half of adult patients. However, since our series included 14 (14) 2 (9) a Infections were cystitis (n ϭ 48), prostatitis (n ϭ 1), and pyelonephritis (n ϭ 1). b Infections included pneumonia (n ϭ 14) and tracheobronchitis (n ϭ 9). c Infections were cellulitis (n ϭ 11), chronic ulcer infection (n ϭ 7), and necrotizing cellulitis (n ϭ 1).
d Infections were osteomyelitis (n ϭ 2) and cholangitis (n ϭ 1). e Intra-abdominal infection.
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